MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:35Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Antimuscarinics]]
			[[Category:Long-acting muscarinic antagonists]]
			[[Category:Bronchodilators]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #163

2026-05-23T03:56:07Z

parser-claude batch MedTemplate pre-fill, Top 300 #163

New page

{{MedTemplate
| generic = Tiotropium
| brand = Spiriva, Spiriva Respimat
| structure =
| classes = [[:Category:Antimuscarinics|Antimuscarinic]], [[:Category:Long-acting_muscarinic_antagonists|Long-acting muscarinic antagonist (LAMA)]], [[:Category:Bronchodilators|Bronchodilator]]
| uses = <vote slug="copd-controller-use">COPD (maintenance bronchodilation)</vote>, <vote slug="asthma-controller-use">Asthma (severe, add-on to ICS-LABA)</vote>
| starting_dose = 18 mcg DPI once daily (HandiHaler); 2.5 mcg per actuation × 2 inhalations once daily (Respimat)
| preparations = 18 mcg HandiHaler capsules; 2.5 mcg/actuation Respimat solution inhaler (1.25 mcg/actuation for asthma indication)
| fda_max = One dose per day
| pill_id =
| routes = Inhaled (DPI, soft-mist inhaler)
| onset = Bronchodilation 30 minutes; steady-state at 1-2 weeks
| duration = 24 hours (long receptor dissociation half-life from M3)
| halflife = ~25-44 hours plasma; receptor kinetics drive the once-daily duration<ref name="spiriva-label">FDA Prescribing Information, Spiriva HandiHaler (tiotropium bromide), Boehringer Ingelheim, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021395s060lbl.pdf</ref>
| bioavailability = Inhaled lung deposition ~20%; systemic absorption from lung ~33%; oral component negligible<ref name="spiriva-label" />
| pregnancy = Limited data; LABA/LAMA strategies in pregnancy generally favor agents with the most reassuring data.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="tiotropium-mech-claim">Tiotropium is a long-acting muscarinic antagonist binding M1/M2/M3 receptors with markedly slower dissociation from M3 (the airway-relevant subtype) than from M2, producing functional M3 selectivity and 24-hour bronchodilation from once-daily dosing.</vote> Class adverse effects are anticholinergic in nature (dry mouth, urinary retention, blurred vision, constipation), though systemic absorption from inhaled administration is low. Use with caution in narrow-angle glaucoma and bladder-outlet obstruction<ref name="spiriva-label" />.
}}

== References ==
<references />

Tiotropium - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #163